GlassScriptPhysician profile
Gabriel Carabulea
NPI 1063419604
$6,505.80
in general payments reported to CMS, 2019-2025
46 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $757 · 2021: $1,122 · 2022: $1,180 · 2023: $1,519 · 2024: $794 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,486 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,485.59 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $746.06 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $546.62 | 2019-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $437.62 | 2019-2024 | Opdualag, Opdivo |
| Genzyme Corporation | $363.21 | 2019-2022 | |
| Amgen INC. | $351.07 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $310.27 | 2019-2024 | Tagrisso, Imfinzi, Enhertu |
| Lilly USA, LLC | $295.51 | 2019-2023 | Verzenio |
| Merck Sharp & Dohme LLC | $234.95 | 2019-2023 | Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $221.17 | 2019-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $212.86 | 2019-2023 | Reblozyl, Opdualag, Pomalyst |
| Janssen Biotech, INC. | $206.82 | 2019-2025 | Rybrevant |
| Sumitomo Pharma America, INC. | $201.47 | 2023-2024 | Orgovyx |
| Ipsen Biopharmaceuticals, INC | $194.16 | 2019-2023 | Somatuline Depot, Onivyde |
| Novartis Pharmaceuticals Corporation | $179.47 | 2021-2024 | |
| Kite Pharma, INC. | $168.39 | 2021-2023 | Yescarta |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Carabulea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.